Medicare’s Prescription Drug Program: Competition Issues and Cost Trends

Gloria R. Pattinson (Editor)

Series: Health Care in Transition
BISAC: BUS070130

Clear

$140.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people.

The federal government spent $59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was $50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost trends and competition issues of Medicare’s Prescription Drug Program. (Imprint: Nova)

Preface

Chapter 1 - Competition and the Cost of Medicare’s Prescription Drug Program (pp. 1-64)
Anna Cook and Andrew Stocking

Chapter 2 - Effects of Using Generic Drugs on Medicare’s Prescription Drug Spending (pp. 65-106)
Julie Somers

Chapter 3 - Spending Patterns for Prescription Drugs under Medicare Part D (pp. 107-128)
Tamara Hayford

Index

You have not viewed any product yet.